Loading
The mTOR inhibitor everolimus more than doubled the time to progression in advanced pancreatic neuroendocrine tumours, becoming one of the first two targeted drugs approved for the disease in 2011.
Phase 3 placebo-controlled trial of 410 patients with advanced, low- or intermediate-grade, progressive pancreatic neuroendocrine tumours randomised to everolimus 10 mg daily or placebo.
Median progression-free survival was 11.0 versus 4.6 months (hazard ratio 0.35), with stomatitis, rash, diarrhoea and hyperglycaemia as the characteristic toxicities; overall survival was similar because of crossover.
Everolimus is a standard option for progressive pancreatic neuroendocrine tumours, alongside sunitinib, chemotherapy and radioligand therapy.
Shares Pancreatic neuroendocrine tumours, New England Journal of Medicine.
Shares Pancreatic neuroendocrine tumours, New England Journal of Medicine.
Shares Pancreatic neuroendocrine tumours, New England Journal of Medicine.